OncoMatch/Clinical Trials/NCT06026410
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Is NCT06026410 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Darlifarnib and Cabozantinib for solid tumors with hras alterations.
Treatment: Darlifarnib · Cabozantinib · Adagrasib — This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Biomarker criteria
Required: HRAS mutation
HRAS-mutant and/or amplified tumors (any solid tumor type)
Required: HRAS amplification
HRAS-mutant and/or amplified tumors (any solid tumor type)
Required: HRAS overexpression
HRAS overexpression (only for HNSCC tumors)
Required: KRAS mutation
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: KRAS amplification
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: NRAS mutation
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: NRAS amplification
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: HRAS mutation
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: HRAS amplification
KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC
Required: KRAS mutation
KRAS-mutant and/or amplified PDAC
Required: KRAS amplification
KRAS-mutant and/or amplified PDAC
Required: KRAS G12C
KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC
Prior therapy
Must have received: systemic therapy — locally advanced or metastatic RCC with predominantly clear cell subtype
at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype
Must have received: systemic therapy — locally advanced and metastatic RCC (non-clear cell)
non-clear cell RCC patients who are either treatment-naïve or have received any prior systemic treatment for locally advanced and metastatic RCC
Must have received: systemic therapy — locally advanced or metastatic ccRCC
at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic ccRCC, but no more than 3 prior systemic anticancer therapies
Must have received: systemic therapy — KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC
at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC
Cannot have received: FTI or HRAS inhibitor
Prior treatment with an FTI or HRAS inhibitor
Lab requirements
Blood counts
acceptable hematologic function
Kidney function
acceptable renal function
Liver function
acceptable liver function
Cardiac function
inadequate cardiac and/or vascular function, including receipt of treatment for unstable angina, myocardial infarction, and/or cerebrovascular attack within the prior 6 months, mean QTcF ≥470 ms, or Class II or greater congestive heart failure [excluded]
Acceptable liver, renal, endocrine, and hematologic function. Inadequate cardiac and/or vascular function, including receipt of treatment for unstable angina, myocardial infarction, and/or cerebrovascular attack within the prior 6 months, mean QTcF ≥470 ms, or Class II or greater congestive heart failure [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Comprehensive Cancer Center · Phoenix, Arizona
- University of Southern California · Los Angeles, California
- Cedars-Sinai Medical Center · Los Angeles, California
- UCLA Department of Medicine · Los Angeles, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify